LSV Asset Management Takes Position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

LSV Asset Management bought a new position in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 75,053 shares of the company's stock, valued at approximately $2,424,000. LSV Asset Management owned 0.13% of Harmony Biosciences as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in HRMY. Pacer Advisors Inc. boosted its position in Harmony Biosciences by 534,795.2% in the 4th quarter. Pacer Advisors Inc. now owns 1,224,910 shares of the company's stock valued at $39,565,000 after buying an additional 1,224,681 shares during the period. Federated Hermes Inc. grew its position in shares of Harmony Biosciences by 2,132.8% during the 4th quarter. Federated Hermes Inc. now owns 525,337 shares of the company's stock worth $16,968,000 after buying an additional 501,809 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its stake in shares of Harmony Biosciences by 18.3% during the third quarter. Adage Capital Partners GP L.L.C. now owns 1,420,000 shares of the company's stock valued at $46,533,000 after buying an additional 220,000 shares during the period. HealthInvest Partners AB bought a new stake in shares of Harmony Biosciences in the fourth quarter valued at about $4,684,000. Finally, Vanguard Group Inc. lifted its stake in Harmony Biosciences by 2.5% in the third quarter. Vanguard Group Inc. now owns 3,684,152 shares of the company's stock worth $120,730,000 after acquiring an additional 88,295 shares during the period. 86.23% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Jeffrey Dierks sold 11,979 shares of Harmony Biosciences stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $32.00, for a total value of $383,328.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 30.80% of the company's stock.

Harmony Biosciences Stock Down 3.6 %

NASDAQ HRMY traded down $1.14 on Friday, hitting $30.14. The stock had a trading volume of 250,707 shares, compared to its average volume of 397,210. Harmony Biosciences Holdings, Inc. has a 52-week low of $18.61 and a 52-week high of $39.26. The business's fifty day moving average price is $31.05 and its 200 day moving average price is $30.34. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.11 and a quick ratio of 3.07. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of 13.18, a price-to-earnings-growth ratio of 0.51 and a beta of 0.75.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last announced its earnings results on Tuesday, April 30th. The company reported $0.67 earnings per share for the quarter, topping the consensus estimate of $0.60 by $0.07. Harmony Biosciences had a return on equity of 28.26% and a net margin of 22.30%. The firm had revenue of $154.62 million for the quarter, compared to the consensus estimate of $154.10 million. During the same period in the previous year, the business earned $0.48 EPS. The firm's revenue for the quarter was up 29.8% on a year-over-year basis. Equities research analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.53 earnings per share for the current year.

Analyst Ratings Changes

HRMY has been the topic of a number of research reports. Mizuho cut their target price on shares of Harmony Biosciences from $42.00 to $40.00 and set a "buy" rating on the stock in a research report on Tuesday, February 27th. Cantor Fitzgerald reissued an "overweight" rating and issued a $49.00 price objective on shares of Harmony Biosciences in a research note on Friday, April 12th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $50.00 target price on shares of Harmony Biosciences in a research report on Tuesday, April 30th. Two equities research analysts have rated the stock with a sell rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, Harmony Biosciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $40.63.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.